Published in
BMJ Publishing Group, Annals of the Rheumatic Diseases, 6(74), p. 1138-1144, 2014
DOI: 10.1136/annrheumdis-2014-205571
Links
Tools
Pegylated interferon-α-2b reduces corticosteroid requirement in patients with Behçet's disease with upregulation of circulating regulatory T cells and reduction of Th17.
Journal article published in 2014 by
S. Lightman,
S. R. J. Taylor 
,
C. Bunce ,
H. Longhurst,
W. Lynn,
R. Moots,
M. Stanford,
O. Tomkins-Netzer,
D. Yang,
Vl L. Calder,
Do O. Haskard
,
C. Bunce ,
H. Longhurst,
W. Lynn,
R. Moots,
M. Stanford,
O. Tomkins-Netzer,
D. Yang,
Vl L. Calder,
Do O. Haskard
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
To determine whether the addition of 26 weeks of subcutaneous peginterferon-α-2b could reduce the requirement for systemic corticosteroids and conventional immunosuppressive medication in patients with Behçet's disease (BD).